{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inherited+Hematological+Diseases&page=24", "query": { "condition": "Inherited Hematological Diseases", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 2014, "total_pages": 202, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inherited+Hematological+Diseases&page=25&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inherited+Hematological+Diseases&page=23&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T04:59:55.069Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05618301", "title": "Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Motixafortide", "type": "DRUG" }, { "name": "Natalizumab", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2023-07-07", "completion_date": "2025-06-24", "has_results": false, "last_update_posted_date": "2025-08-11", "last_synced_at": "2026-10-16T04:59:55.069Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05618301" }, { "nct_id": "NCT03001830", "title": "Gene Therapy for Haemophilia A.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hemophilia A" ], "interventions": [ { "name": "AAV2/8-HLP-FVIII-V3", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University College, London", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 14, "start_date": "2017-06-14", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2025-03-05", "last_synced_at": "2026-10-16T04:59:55.069Z", "location_count": 3, "location_summary": "Boise, Idaho • Lexington, Kentucky • Memphis, Tennessee", "locations": [ { "city": "Boise", "state": "Idaho" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03001830" }, { "nct_id": "NCT07474428", "title": "Quality of Life in Pediatric Participants With HHT", "overall_status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hereditary Haemorrhagic Telangiectasia (HHT)" ], "interventions": [], "intervention_types": [], "sponsor": "Ashley Nelson", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "2 Years to 25 Years" }, "enrollment_count": 70, "start_date": "2026-07", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-10-16T04:59:55.069Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07474428" }, { "nct_id": "NCT05611801", "title": "A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hemophilia A", "Hemophilia B" ], "interventions": [ { "name": "marstacimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "MALE", "summary": "1 Year to 17 Years · Male only" }, "enrollment_count": 100, "start_date": "2022-12-09", "completion_date": "2028-09-10", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-16T04:59:55.069Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05611801" }, { "nct_id": "NCT07780981", "title": "Impact of Body Positioning on EndoFLIP Measurements: A Comparative Study of Supine and Left Lateral Decubitus Positions", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Dysphagia", "Esophageal Stricture", "Epidermolysis Bullosa (EB)", "Achalasia", "Esophageal Motility Disorders", "Eosinophilic Esophagitis (EoE)" ], "interventions": [ { "name": "EndoFlip", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "5 Years to 21 Years" }, "enrollment_count": 25, "start_date": "2026-07-24", "completion_date": "2028-07-01", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-16T04:59:55.069Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07780981" }, { "nct_id": "NCT02143830", "title": "HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fanconi Anemia", "Severe Marrow Failure", "Myelodysplastic Syndrome (MDS)", "Acute Myelogenous Leukemia (AML)" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "rabbit ATG", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Peripheral blood stem cell", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Months", "maximum_age": null, "sex": "ALL", "summary": "3 Months and older" }, "enrollment_count": 70, "start_date": "2014-04", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-10-16T04:59:55.069Z", "location_count": 3, "location_summary": "New York, New York • Cincinnati, Ohio • Seattle, Washington", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02143830" }, { "nct_id": "NCT01408030", "title": "North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Telangiectasia, Hereditary Hemorrhagic", "Epistaxis" ], "interventions": [ { "name": "Sterile saline", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Estriol", "type": "DRUG" }, { "name": "Tranexamic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "James Gossage", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 123, "start_date": "2011-08", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2018-10-19", "last_synced_at": "2026-10-16T04:59:55.069Z", "location_count": 6, "location_summary": "Los Angeles, California • Augusta, Georgia • Baltimore, Maryland + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01408030" }, { "nct_id": "NCT00459212", "title": "GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Undifferentiated Leukemia", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Blastic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Untreated Adult Acute Lymphoblastic Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "GTI-2040", "type": "DRUG" }, { "name": "pharmacological study", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2007-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-12-04", "last_synced_at": "2026-10-16T04:59:55.069Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00459212" }, { "nct_id": "NCT00600665", "title": "Effectiveness of a Computerized Tool (PAINRelieveIt) to Help Manage Pain Related to Sickle Cell Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anemia, Sickle Cell", "Hemoglobin SC Disease" ], "interventions": [ { "name": "PAINReportIt (Phase 1 + 2)", "type": "BEHAVIORAL" }, { "name": "PAINUCope (Phase 1)", "type": "BEHAVIORAL" }, { "name": "PAINConsultN (Phase 2)", "type": "BEHAVIORAL" }, { "name": "PAINUCope (Phase 2)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 279, "start_date": "2007-02", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-10-16T04:59:55.069Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00600665" }, { "nct_id": "NCT05248594", "title": "Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hemophilia A" ], "interventions": [ { "name": "HEMLIBRA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "36 Months", "sex": "ALL", "summary": "Up to 36 Months" }, "enrollment_count": 71, "start_date": "2024-08-01", "completion_date": "2025-07-18", "has_results": false, "last_update_posted_date": "2025-09-08", "last_synced_at": "2026-10-16T04:59:55.069Z", "location_count": 10, "location_summary": "Hartford, Connecticut • New Haven, Connecticut • Lebanon, New Hampshire + 7 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Newark", "state": "New Jersey" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05248594" } ] }